Vaxart (VXRT) Q2 2024 earnings summary

Executive summary

• Secured up to $453 million in BARDA funding for a Phase IIb COVID-19 oral vaccine trial, advancing the platform as a next-generation solution for pandemic threats.

• Achieved positive clinical results in the norovirus program, including Phase I data in lactating mothers and encouraging Phase II challenge data.

• Focused on advancing oral pill vaccine technology targeting mucosal immunity for infectious diseases, with strategic prioritization of COVID-19 and norovirus programs; RSV deprioritized.

• Completed equity offerings raising $56.3 million net in H1 2024, increasing authorized common stock to 350 million shares.

• Cash runway extended into 2026, supporting execution of regulatory and clinical milestones.

Financial highlights

• Q2 2024 revenue was $6.4 million, up from $1.4 million in Q2 2023, primarily from BARDA/government contracts; H1 2024 revenue was $8.6 million, up from $2.0 million year-over-year.

• Net loss for Q2 2024 was $16.5 million, improved from $22.6 million in Q2 2023; net loss per share was $0.09, improved from $0.16.

• Operating expenses decreased 7% year-over-year to $22.7 million in Q2 2024; R&D expenses were $17.5 million, G&A $5.2 million.

• Cash, cash equivalents, and investments totaled $62.6 million as of June 30, 2024, with an additional $64.7 million received post-quarter from BARDA.

• Weighted average shares outstanding increased to 184.7 million in Q2 2024 from 139.6 million in Q2 2023 due to equity offerings.

Outlook and guidance

• Phase IIb COVID-19 trial expected to initiate in the second half of 2024, pending FDA alignment and regulatory feedback.

• Interim efficacy analysis planned after 255 symptomatic COVID-19 cases; primary analysis after 12 months post-vaccination.

• Ongoing FDA discussions for both COVID-19 and norovirus programs to determine next regulatory steps and potential Phase IIb/III studies.

• Management expects existing funds to support operations into 2026, with additional capital needs dependent on future development and commercialization progress.

• Continued investment in innovation and clinical advancement supported by strong capital position.